These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 38441582)
1. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. Ruberg FL; Maurer MS JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582 [TBL] [Abstract][Full Text] [Related]
2. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788 [TBL] [Abstract][Full Text] [Related]
3. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421 [TBL] [Abstract][Full Text] [Related]
4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy. Paton DM Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875 [TBL] [Abstract][Full Text] [Related]
5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy. Lamb YN Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827 [TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808 [TBL] [Abstract][Full Text] [Related]
7. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Buxbaum JN; Ruberg FL Genet Med; 2017 Jul; 19(7):733-742. PubMed ID: 28102864 [TBL] [Abstract][Full Text] [Related]
9. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442 [TBL] [Abstract][Full Text] [Related]
10. DISCOVERY: prevalence of transthyretin ( Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532 [TBL] [Abstract][Full Text] [Related]
11. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226 [TBL] [Abstract][Full Text] [Related]
13. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
14. Therapy of ATTR Cardiac Amyloidosis: Current Indications. Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119 [TBL] [Abstract][Full Text] [Related]